Navigation Links
Cellectis Publishes 2010 Financial Results
Date:3/31/2011

PARIS, March 31, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the genome engineering specialist, has announced its consolidated financial results for the financial year ended December 31, 2010.

Main financial items:

  • Total operating revenues increased by 55% between 2009 and 2010, from EUR 10.1M to EUR 15.8M. Growth was mainly driven by the increase in the Credit d'Impot Recherche, as a result of several major contracts (Boehringer Ingelheim, Bayer Healthcare and BASF Plant Science) and also by the consolidation of existing partnerships.

  • The development of subsidiaries and acquisition of complementary technologies led to an increase in operating expenses, totaling EUR 27.2M, up 37% from 2009.  

  • The net loss reached EUR 8M, slightly lower than the loss published for 2009, on a comparable basis.

  • The cash position came to EUR 24M at the end of 2010. Its evolution vs. 2009 was, for a third, due to temporary or non-recurring reasons: i/ the temporary augmentation of working capital requirement (Credit d'Impot Recherche increased by EUR 5M), and ii/ the acquisition of CytoPulse Inc.'s patents for EUR 1.5M.

  • Commenting on these results, Marc Le Bozec, Cellectis Chief Financial Officer, explained that "2010 was a year marked by the expansion of our technology and the development of our organization to support our research and marketing efforts. We significantly increased the sales effort of Cellectis bioresearch, formally structured our activities in the area of agrobiotechnology, and secured access to technologies that will help us to shorten the timeframe for bringing products into the market in the coming months."

    Key figures(based on IFRS -- International Financial Reporting Standards):

  • The company has decided to present, from now on, complete consolidated results according to IFRS, with more detail than the non-audited cons
    '/>"/>

  • SOURCE Cellectis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
    2. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
    3. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
    4. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
    5. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
    6. Cellectis Unveils Its New Corporate Website
    7. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
    8. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
    9. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
    10. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
    11. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/29/2014)... Each year in the US, more ... In the military, burn injury is a ubiquitous ... care. More than 800 service members sustained burn ... slowly, remain inflamed and often become infected, producing ... functionally damaging. While developments in supportive care have ...
    (Date:9/29/2014)... Biotech Inc. ("Portage" or "the Company") (OTC: PTGEF, Canadian ... three Promissory Note holders, two of whom are the ... July 2014 for a total of $ 300,000 opted ... 3,500,001 restricted common shares. Notes were repayable within one ... the coupon were convertible into common shares to be ...
    (Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
    (Date:9/29/2014)... METTLER TOLEDO’s new line of XPE ... precision balances as well as automated dosing ... can carry out their daily weighing tasks worry free, ... deliver consistently reliable and compliant results, thanks to new ... of the biggest challenges in analytical and micro-analytical weighing ...
    Breaking Biology Technology:Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3New Line of XPE Balances from METLER TOLEDO is Designed for High Performance and Ease of Compliance 2
    ... This release is available in German . ... in electronics. Dr. Willi Auwaerter and Professor Johannes Barth, together ... (TUM), have now presented a novel molecular switch in the ... the switch is the position of a single proton in ...
    ... COLUMBUS, Ohio, Dec. 12, 2011   Chemical Abstracts ... Chemical Society and the world,s authority for chemical ... InfoChem, GmbH (InfoChem), a  leader ... as datamining in chemical science documents, headquartered in ...
    ... Zyngenia , Inc ... antibody-based drugs called Zybodies™, announced today that it has promoted ... and appointed Daniel L. Menichella as ... our start in September 2009, Zyngenia has made tremendous progress in ...
    Cached Biology Technology:The smallest conceivable switch 2CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics 2CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics 3Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 2Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 3
    (Date:9/29/2014)... the age of dinosaurs, gigantic reptilesdistant relatives of modern ... in water and it was thought they didn,t much ... Tennessee, Knoxville, researcher in the thigh of one of ... Stephanie Drumheller, an earth and planetary sciences lecturer, and ... examined 220-million-year-old bite marks in the thigh bones of ...
    (Date:9/29/2014)... considered capable of doing anything on their own. But ... water. In the future, such moving droplets may deliver ... to be self-moving is a feature normally ... be self-moving, report researchers from University of Southern Denmark ... , The researchers have made alcohol droplets move in ...
    (Date:9/29/2014)... researchers at the University of Cambridge has shown that ... most of Greenland is more sensitive to climate change ... rising sea levels that threaten coastal communities worldwide. , ... levels of meltwater created and spilled into the ocean ... new model also takes into account the role that ...
    Breaking Biology News(10 mins):Tooth serves as evidence of 220 million-year-old attack 2Scientists make droplets move on their own 2Greenland Ice Sheet more vulnerable to climate change than previously thought 2Greenland Ice Sheet more vulnerable to climate change than previously thought 3
    ... a telescope promise to make it easier for people ... requiring sharper distance vision. Schepens Eye Research Institute scientists ... devices in an article published in the May/June issue ... in print form to subscribers this month. ...
    ... A new study by researchers from Columbia University,s ... most challenging issues in infant health and preventing mother-to-child ... HIV-infected mothers had been advised that for the best ... by a rapid weaning four to six months after ...
    ... Pennsylvania State University College of Medicine, Hershey, Pennsylvania have ... immune response modifier with potent antiviral and antitumor activity, ... (OGFr) axis for its action. This discovery, reported ... and Medicine , provides new insights into a widely ...
    Cached Biology News:Telescope embedded in glasses lens promises to make driving easier for visually impaired 2Telescope embedded in glasses lens promises to make driving easier for visually impaired 3Early cessation of breastfeeding by HIV+ women in poor countries and child survival 2Early cessation of breastfeeding by HIV+ women in poor countries and child survival 3Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2
    Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
    pH-insensitive fluorescence (pH 2-12)...
    Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
    Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
    Biology Products: